FSD Pharma announces appointment of Dr Eleanor N. Fish to its Research and Clinical Advisory Board
Published: 09:29 16 Nov 2021 EST
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said it has expanded its team by appointing Dr Eleanor N. Fish to its Research and Clinical Advisory Board.
The Toronto-based company said that Dr Fish would bring key expertise to support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis.
Dr Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the Government of Canada’s Expert Scientific Panel to the chief scientific advisor.
READ: FSD Pharma strikes deal with Covar Pharmaceuticals to support the development of drug candidate Lucid-PSYCH
“I am delighted to welcome Dr Eleanor Fish to our team,” said Lakshmi P. Kotra, CEO of Lucid Psycheceuticals Inc., FSD Pharma (CSE:HUGE, NASDAQ:HUGE)’s wholly-owned subsidiary.
“A key aspect of Eleanor’s research is to better understand the onset and treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Her expertise and insights will be extremely valuable as we continue to advance our FSD-PEA and Lucid-MS programs, and her decades of experience in translational research will greatly benefit FSD’s current and future pipelines,” added Kotra.
Dr Fish is a professor in the Department of Immunology at the University of Toronto; Associate Chair of International Initiatives and Collaborations at the University of Toronto; and Emerita Scientist at the Toronto General Hospital Research Institute of the University Health Network.
She has a B.Sc. from the University of Manchester, an M.Phil. from King's College at the University of London, and a Ph.D. from the Institute of Medical Sciences at the University of Toronto. Dr Fish has received numerous international awards recognizing her scientific achievements and has authored more than 170 peer-reviewed scientific papers published in international journals.
“I am energized by this opportunity to assist FSD Pharma (CSE:HUGE, NASDAQ:HUGE) in advancing the development of its next-generation therapeutics in pursuit of a healthier world,” Dr Fish said in a statement.
FSD Pharma, with its two wholly-owned subsidiaries, is dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services.
Lucid Psycheceuticals has exclusive worldwide rights to novel compounds shown to prevent and potentially reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, FSD is seeking to develop a unique psychoactive (psychedelic-based) therapeutic aimed at addressing neurodegenerative disorders, a multibillion-dollar mental health market.
Contact Ritika at ritika@proactiveinvestors.com
